ID | Age | Ethnicity | Race | BMI (kg/m2) | Diagnosis at Admission | Days on Lamotrigine at Baseline Assessment | Total Days on Lamotrigine | Final Lamotrigine Dose (mg/day) | Concurrent Medications |
---|---|---|---|---|---|---|---|---|---|
1 | 28 | Non-Hispanic | Black | 26.3 | EDNOSa | −2 | 223 | 150 | quetiapine XR, bupropion XL, levomilnacipran |
2 | 23 | Non-Hispanic | White | 20.2 | EDNOSb | −5 | 246 | 200 | duloxetine, trazodone |
3 | 41 | Non-Hispanic | White | 21.9 | EDNOSc | −4 | 253 | 100 | escitalopram |
4 | 42 | Hispanic | Other | 28.3 | BN | 1 | 190 | 100 | venlafaxine XR, naltrexone |
5 | 18 | Non-Hispanic | White | 19.7 | AN-BP | 1 | 86 | 200 | sertraline, gabapentin |
6 | 31 | Non-Hispanic | White | 20.1 | AN-BP | 1 | 85 | 200 | gabapentin, naltrexone |
7 | 25 | Non-Hispanic | White | 19.1 | AN-R | 0 | 102 | 200 | duloxetine, sertralined |
8 | 31 | Hispanic | Other | 22.3 | AN-BP | 0 | 71 | 100 | fluoxetine |
9 | 32 | Non-Hispanic | Other | 25.7 | BN | 1 | 71 | 200 | duloxetine |